Regeneron Pharmaceuticals, Inc. (REGN)
|Net Income (ttm)||4.00B|
|Trading Day||May 18|
|Day's Range||513.68 - 526.96|
|52-Week Range||441.00 - 664.64|
Stocks that soar or plunge get all the attention.
Phase 3 Data Presented at ATS 2021 Show REGEN-COV™ (casirivimab with imdevimab) Reduced Risk of Hospitalization or De...
TARRYTOWN, N.Y., May 17, 2021 /PRNewswire/ -- Patients treated with REGEN-COV had 4-day shorter duration of symptoms and significantly reduced viral load compared to placebo Similar efficacy observed w...
Pivotal data at ATS 2021 show Dupixent® (dupilumab) significantly reduced asthma attacks and improved lung function i...
Pivotal d ata at ATS 2021 s how Dupixent ® (dupilumab) s ignificantly r educed a sthma a ttacks and i mproved l ung f unction in c hildren
Pivotal Data at ATS 2021 Show Dupixent® (dupilumab) Significantly Reduced Asthma Attacks and Improved Lung Function i...
TARRYTOWN, N.Y. and PARIS, May 17, 2021 /PRNewswire/ -- Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma in a r...
Positive Phase 3 Libtayo® (cemiplimab) Results in Advanced Cervical Cancer Presented at ESMO Virtual Plenary
TARRYTOWN, N.Y. and PARIS, May 12, 2021 /PRNewswire/ -- Libtayo is the first immunotherapy to demonstrate an improvement in overall survival in advanced cervical cancer, as well as progression-free surv...
Regeneron (REGN) beats on Q1 earnings while sales record strong year-over-year growth on solid performance of Dupixent and Eylea, and incremental contribution from REGEN-COV.
The big biotech delivered impressive revenue and earnings growth.
The shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) are rising on the company's upbeat first-quarter earnings report, which boasted a rise in profits to $9.89 per share -- toppling analysts' estim...
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned $9.89 per share for the first quarter, beating the $9.03 estimate. Revenue of $2.53 billion narrowly missed analyst consensus of $2.56 billion.
Regeneron (REGN) delivered earnings and revenue surprises of 12.51% and -1.96%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Regeneron Pharmaceuticals Inc reported a 78% rise in first-quarter profit on Thursday, helped by a robust recovery in demand for its eye drug Eylea.
TARRYTOWN, N.Y., May 6, 2021 /PRNewswire/ -- First quarter 2021 revenues increased 38% to $2.53 billion versus first quarter 2020; revenues excluding REGEN-COV TM(1) increased 20% First quarter 2021 EYL...
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Regeneron (REGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Roche Holdings AG (OTCMKTS: RHHBY) has received Emergency Use Authorization in India for its investigational antibody cocktail (casirivimab and imdevimab) for treatment of COVID-19. Cipla will partner f...
Tom Gayner (Trades, Portfolio), chief investment officer of Markel Corp. ( MKL , Financial), disclosed this week that his firm's top five trades during the first quarter included a new buy in Regeneron ...
Investors are likely to focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports first-quarter 2021 results.
ATS 2021 Breaking News Session to Feature Pivotal Data on REGEN-COV™ (casirivimab with imdevimab) and Dupixent® (dupi...
TARRYTOWN, N.Y., May 3, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that positive Phase 3 data from trials evaluating two Regeneron medicines will be featured at ...
In the latest trading session, Regeneron (REGN) closed at $485, marking a -0.57% move from the previous day.
Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
A new delivery method for its COVID-19 treatment may offer a boost.
In the latest trading session, Regeneron (REGN) closed at $488.64, marking a -0.36% move from the previous day.
TARRYTOWN, N.Y., April 23, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: Bank of America Securities Virtual Health Care Conference...
New Dupixent® (dupilumab) Analyses at Two Upcoming Dermatology Congresses Reinforce Long-term Safety and Efficacy Pro...
TARRYTOWN, N.Y., April 23, 2021 /PRNewswire/ -- Nearly 30 data presentations at AAD and ESPD highlight the impact of Dupixent on disease measures including rapid itch relief and sustained improvement i...
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The biotech's antibody therapy continues to show promise. But there's considerable uncertainty about its long-term prospects.
Over the past few months we have maintained our view that Regeneron stock looks undervalued. The stock has largely been in focus since last year amid the development of REGEN-COV, its Covid-19 antibody ...
They're among the top 10 holdings in one of Ark Invest's biggest funds.
And they all have one key thing in common.
"I think that the left-behind health care stocks are now coming back to life at the expense of the cyclical growth plays," the "Mad Money" host said.
Regeneron's antibody drug offers strong protection against Covid-19
A new study shows Regeneron's antibody cocktail can offer strong protection against Covid-19, but Regeneron's antibody cocktail still needs FDA approval for the drug to be used for preventative use. Meg...
Nearly everyone will get the Covid-19 vaccination, suggesting strong revenue for a handful of pharmaceutical companies. The post Vaccine Passport Potential Could Boost These 7 Pharmaceutical Stocks appe...
Regeneron (REGN) announces encouraging data on antibody cocktail, REGEN-COV, from two phase III studies.
Regeneron CEO on FDA request for expanded EUA of Covid antibody drug
Regeneron Pharmaceuticals said Monday it will ask the Food and Drug Administration to allow its Covid-19 antibody therapy to be used as a preventative treatment. Regeneron CEO Leonard Schleifer joined "...
Phase 3 Treatment Trial in Recently Infected Asymptomatic Patients Showed REGEN-COV™ (casirivimab with imdevimab) Sig...
TARRYTOWN, N.Y., April 12, 2021 /PRNewswire/ -- Second Phase 3 trial undertaken in collaboration with NIAID to announce results today, both using subcutaneous administration of REGEN-COV in asymptomatic...
Regeneron said a phase three clinical trial of the drug reduced the risk of symptomatic infections in individuals by 81%.
Phase 3 Prevention Trial Showed 81% Reduced Risk of Symptomatic SARS-CoV-2 Infections with Subcutaneous Administratio...
TARRYTOWN, N.Y., April 12, 2021 /PRNewswire/ -- REGEN-COV rapidly protected household contacts from exposure to SARS-CoV-2 at home, with 72% protection against symptomatic infections in the first week,...
NIH COVID-19 Treatment Guidelines Strongly Recommend Use of REGEN-COV™ (casirivimab with imdevimab) in Outpatients at...
TARRYTOWN, N.Y., April 9, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that newly updated National Institutes of Health (NIH) COVID-19 Treatment Guidelines strongl...
Regeneron to Report First Quarter 2021 Financial and Operating Results and Host Conference Call and Webcast on May 6,...
TARRYTOWN, N.Y., April 6, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2021 financial and operating results on Thursday, May ...
Their growth prospects are too good to ignore.
There are a couple of obstacles that could get in the way.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent i... [Read more...]
|IPO Date |
Apr 2, 1991
|Stock Exchange |
|Ticker Symbol |
In 2020, REGN's revenue was $8.50 billion, an increase of 29.58% compared to the previous year's $6.56 billion. Earnings were $3.51 billion, an increase of 66.05%.
According to 27 analysts, the average rating for REGN stock is "Buy." The 12-month stock price forecast is 628.36, which is an increase of 21.38% from the latest price.